secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001193125-25-237904
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics expects $486.2M cash as of Sept 30, 2025
-----------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and marketable securities of ~$486.2M as of Sept 30, 2025.
- Full Q3 2025 financial results not yet finalized; subject to completion of closing procedures.
- Company cautions that final amount may differ materially from preliminary estimate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525237904/0001193125-25-237904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525237904/d85106d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-237904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer